Zobrazeno 1 - 10
of 227
pro vyhledávání: '"Shigeki Ohtake"'
Autor:
Satoshi Nishiwaki, Isamu Sugiura, Shin Fujisawa, Yoshihiro Hatta, Yoshiko Atsuta, Noriko Doki, Shingo Kurahashi, Yasunori Ueda, Nobuaki Dobashi, Tomoya Maeda, Yasuhiro Taniguchi, Masatsugu Tanaka, Shinichi Kako, Tatsuo Ichinohe, Takahiro Fukuda, Shigeki Ohtake, Yuichi Ishikawa, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki, on behalf of Japan Adult Leukemia Study Group
Publikováno v:
HemaSphere, Vol 7, Iss 6, p e899 (2023)
Externí odkaz:
https://doaj.org/article/d7e5a0987ca542338d175708144ea6e9
Autor:
Yuki Fujioka, Daisuke Sugiyama, Itaru Matsumura, Yosuke Minami, Masatomo Miura, Yoshiko Atsuta, Shigeki Ohtake, Hitoshi Kiyoi, Yasushi Miyazaki, Hiroyoshi Nishikawa, Naoto Takahashi
Publikováno v:
Cancers, Vol 13, Iss 23, p 5904 (2021)
Treatment-free remission (TFR) has become a therapeutic goal in chronic myeloid leukemia (CML), and approximately half of the patients with chronic phase-CML (CML-CP) with deep molecular remission (DMR) by tyrosine-kinase inhibitors (TKIs) have achie
Externí odkaz:
https://doaj.org/article/e877c71ed0c34e60965b985606eb7a35
Autor:
Akihiro Takeshita, Norio Asou, Yoshiko Atsuta, Hiroaki Furumaki, Toru Sakura, Yasunori Ueda, Masashi Sawa, Nobuaki Dobashi, Yasuhiro Taniguchi, Rikio Suzuki, Masaru Nakagawa, Shigehisa Tamaki, Maki Hagihara, Katsumichi Fujimaki, Hitoshi Minamiguchi, Hiroyuki Fujita, Masamitsu Yanada, Yoshinobu Maeda, Noriko Usui, Yukio Kobayashi, Hitoshi Kiyoi, Shigeki Ohtake, Itaru Matsumura, Tomoki Naoe, Yasushi Miyazaki, the Japan Adult Leukemia Study Group
Publikováno v:
Cancers, Vol 12, Iss 6, p 1444 (2020)
Background: After long-term analysis of the JALSG-APL204 study we recently reported that maintenance therapy with tamibarotene was more effective than all-trans retinoic acid (ATRA) by reducing relapse in APL patients. Here, the clinical significance
Externí odkaz:
https://doaj.org/article/aebcdb6e50ea4cdbbbb66af997b35a70
Autor:
Naoto Takahashi, Taiichi Kyo, Yasuhiro Maeda, Takashi Sugihara, Kensuke Usuki, Tatsuya Kawaguchi, Noriko Usui, Shinichiro Okamoto, Yokiko Ohe, Shigeki Ohtake, Kunio Kitamura, Masahide Yamamoto, Hirofumi Teshima, Toshiko Motoji, Toshiharu Tamaki, Kenichi Sawada, Kazuma Ohyashiki
Publikováno v:
Haematologica, Vol 97, Iss 6 (2012)
It was recently recognized that some chronic myeloid leukemia patients with a complete molecular response could sustain that response after discontinuation of imatinib. To characterize the clinical outcomes and profiles of chronic phase chronic myelo
Externí odkaz:
https://doaj.org/article/098a34917a454b42b4a4f7f57354be4c
Autor:
J. Luis Espinoza, Akiyoshi Takami, Makoto Onizuka, Hiroshi Sao, Hideki Akiyama, Koichi Miyamura, Shinichiro Okamoto, Masami Inoue, Yoshinobu Kanda, Shigeki Ohtake, Takahiro Fukuda, Yasuo Morishima, Yoshihisa Kodera, Shinji Nakao
Publikováno v:
Haematologica, Vol 94, Iss 10 (2009)
Background NKG2D, an activating and co-stimulatory receptor expressed on natural killer cells and T cells, plays pivotal roles in immunity to microbial infections as well as in cancer immunosurveillance. This study examined the impact of donor and re
Externí odkaz:
https://doaj.org/article/e1758e56609c43f18240ee65d6ef5dc2
Autor:
Masamitsu Yanada, Jin Takeuchi, Isamu Sugiura, Hideki Akiyama, Noriko Usui, Fumiharu Yagasaki, Kazuhiro Nishii, Yasunori Ueda, Makoto Takeuchi, Shuichi Miyawaki, Atsuo Maruta, Hiroto Narimatsu, Yasushi Miyazaki, Shigeki Ohtake, Itsuro Jinnai, Keitaro Matsuo, Tomoki Naoe, Ryuzo Ohno
Publikováno v:
Haematologica, Vol 93, Iss 2 (2008)
To identify factors associated with relapse-free survival (RFS), 80 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia, enrolled in a phase II study of imatinib-combined chemotherapy, were analyzed. The median
Externí odkaz:
https://doaj.org/article/5e4b4da313874836a8be830d424b4481
Autor:
Satoshi Nishiwaki, Isamu Sugiura, Shin Fujisawa, Yoshihiro Hatta, Noriko Doki, Shingo Kurahashi, Yasunori Ueda, Nobuaki Dobashi, Tomoya Maeda, Yasuhiro Taniguchi, Masatsugu Tanaka, Shinichi Kako, Tatsuo Ichinohe, Takahiro Fukuda, Yoshiko Atsuta, Shigeki Ohtake, Yuichi Ishikawa, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki
Publikováno v:
Blood. 140:6030-6032
Autor:
Yasuhito Nannya, Magnus Tobiasson, Shinya Sato, Elsa Bernard, Shigeki Ohtake, June Takeda, Maria Creignou, Lanying Zhao, Manabu Kusakabe, Yuhei Shibata, Nobuhiko Nakamura, Mizuki Watanabe, Nobuhiro Hiramoto, Yusuke Shiozawa, Yuichi Shiraishi, Hiroko Tanaka, Kenichi Yoshida, Nobuyuki Kakiuchi, Hideki Makishima, Masahiro Marshall Nakagawa, Kensuke Usuki, Mitsumasa Watanabe, Kazunori Imada, Hiroshi Handa, Masataka Taguchi, Toru Kiguchi, Kazuma Ohyashiki, Takayuki Ishikawa, Akifumi Takaori-Kondo, Hisashi Tsurumi, Senji Kasahara, Shigeru Chiba, Tomoki Naoe, Satoru Miyano, Elli Papaemmanuil, Yasushi Miyazaki, Eva Hellström Lindberg, Seishi Ogawa
Publikováno v:
Blood Advances.
Azacitidine is a mainstay of therapy for MDS-related diseases. The purpose of our study is to elucidate the effect of gene mutations on hematological response and overall survival (OS), particularly focusing on their post-treatment clone size. We enr
Autor:
Ken Ishiyama, Noriharu Nakagawa, Kensuke Usuki, Satoru Takada, Tatsuki Tomikawa, Hiroshi Handa, Yuna Katsuoka, Daiki Hirano, Nobuo Sezaki, Masahiko Sumi, Shin Fujisawa, Yasuhiro Taniguchi, Atsuko Mugitani, Takuro Yoshimura, Eiichi Ohtsuka, Ken Takase, Youko Suehiro, Shuichi Ota, Tomohiro Kajiguchi, Tomoya Maeda, Masahide Yamamoto, Shigeki Ohtake, Akira Katsumi, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is the sole curative therapy for myelodysplastic syndromes (MDS). However, whether bridging therapy (BRT) including azacitidine (AZA) and combination chemotherapy (CCT) prior to allo-SCT s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b739a6d580d7bb7f9e5237a9f936326c
https://doi.org/10.21203/rs.3.rs-2271688/v1
https://doi.org/10.21203/rs.3.rs-2271688/v1
Autor:
Fumihiko Hayakawa, Tomoko Hata, Yasushi Miyazaki, Shigeki Ohtake, Mitsuhiro Matsuda, Masahiro Onoda, Isamu Sugiura, Yukiyasu Ozawa, Maki Hagihara, Yukio Kobayashi, Tomoki Naoe, Toru Sakura, Noriko Doki, Hiroyuki Fujita, Hisayuki Yokoyama, Yoshihiro Hatta, Ryuko Cho, Yuichi Ishikawa, Nobuhiro Hiramoto, Masatsugu Tanaka, Toshiro Ito, Nobuaki Dobashi, Shinichi Kako, Tsuyoshi Kamae, Yasuhiro Taniguchi, Masaaki Tsuji, Shin Fujisawa, Yasunori Ueda, Yoshiko Atsuta, Satoshi Nishiwaki, Daiki Hirano, Youko Suehiro
Publikováno v:
Blood Advances
Key Points Dasatinib-based 2-step induction resulted in a 100% CR rate with minimal toxicities and 53% MRD negativity.This protocol treatment increased the number of HSCTs in CR1, thereby improving 3-year EFS.
Visual Abstract
The standard t
Visual Abstract
The standard t